Quarterly Report January – March 2017
January – March 2017 · Consolidated sales for the first quarter amounted to SEK 5.3 (12.9) million, a decrease of 58%. · Gross profit for the quarter amounted to SEK 4.1 (8.0) million, a decrease of 49%. · Gross profit for the quarter amounted to SEK 0.3 (4.0) million, a decrease of 92%. · Earnings per share were 0:00 (0:15) SEK for the quarter. · Cash and cash equivalents was SEK 25.6 (26.6) million at the end of the period.Significant events during the first quarter of 2017 The European Medicines Agency EMA recommended a temporary